← All trials
NCT04849429
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2021
- Primary completion
- Mar 15, 2022
- Completion date
- Mar 15, 2022
- First posted
- Apr 19, 2021
- Last posted
- Apr 19, 2021
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Anupam HospitalLead sponsor
- Anupam HospitalReponsible party - principal investigator
- Anupam HospitalOverall official - principal investigator
- PHOENIX HELSE NorwayOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.